The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019: (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	$ (542,235)	$ (478,983)
Intangible Assets, Gross (Excluding Goodwill)	6,159,067	5,737,194
Intangible Assets, Net (Excluding Goodwill)	5,616,832	5,258,211
Multiple Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-Lived Trademarks	325,648	294,813
Indefinite-lived Intangible Assets (Excluding Goodwill)	325,648	294,813
Approved Hormone Therapy Drug Candidate Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	3,763,022	3,463,082
Finite-Lived Intangible Assets, Accumulated Amortization	(542,235)	(478,983)
Finite-Lived Intangible Assets, Net	$ 3,220,787	$ 2,984,099
Finite-Lived Intangible Assets, Remaining Amortization Period	12 years 9 months	13 years
Hormone Therapy Drug Candidate Patents - (Pending) [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 2,070,397	$ 1,979,299
Finite-Lived Intangible Assets, Net	$ 2,070,397	$ 1,979,299